Stage FocusSeries A, Series B+
GeographyChina, US
TypeVC
Last Activity2024
Industry Focus
Industries
BiotechMedtechSynthetic Biology
Technical BenchStrong
Investor TypeDeepTech Specialist
ExposureMostly DeepTech Investments
Bio
Lilly Asia Ventures is a biomedical venture capital firm. Fund VII closed at its $700M hard cap in 2024, with total AUM exceeding $1.2B across 6 funds. Fund VI was $1.35B ($900M core plus $450M opportunity vehicle). The firm was originally associated with Eli Lilly but now operates as an independent biomedical specialist.
The tri-geography model covers Shanghai (China HQ), Hong Kong (Asia hub), a...
Similar Funds
Ally Bridge Group
New York, United States
DeepTech NativeBiotechMedtechSeries ASeries B+
Genoa Ventures
San Francisco, United States
DeepTech NativeBiotechSynthetic BiologyMedtechSeedSeries A
Leaps by Bayer
Leverkusen, Germany
DeepTech NativeBiotechAgritechMedtechSeedSeries A
LYFE Capital
Singapore
DeepTech NativeBiotechMedtechRoboticsSeries ASeries B+
Sherpa Healthcare Partners
Shanghai, China
DeepTech NativeBiotechMedtechSynthetic BiologySeries ASeries B+
Sofinnova Partners
Paris, France
DeepTech NativeBiotechMedtechClimate TechSeedSeries A